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Abstract
Background: In order to facilitate and improve the use of antiretroviral therapy (ART), international recommendations are
released and updated regularly. We aimed to study if adherence to the recommendations is associated with better
treatment outcomes in the Swiss HIV Cohort Study (SHCS).
Methods: Initial ART regimens prescribed to participants between 1998 and 2007 were classified according to IAS-USA
recommendations. Baseline characteristics of patients who received regimens in violation with these recommendations
(violation ART) were compared to other patients. Multivariable logistic and linear regression analyses were performed to
identify associations between violation ART and (i) virological suppression and (ii) CD4 cell count increase, after one year.
Results: Between 1998 and 2007, 4189 SHCS participants started 241 different ART regimens. A violation ART was started in
5% of patients. Female patients (adjusted odds ratio aOR 1.83, 95%CI 1.28–2.62), those with a high education level (aOR
1.49, 95%CI 1.07–2.06) or a high CD4 count (aOR 1.53, 95%CI 1.02–2.30) were more likely to receive violation ART. The
proportion of patients with an undetectable viral load (,400 copies/mL) after one year was significantly lower with violation
ART than with recommended regimens (aOR 0.54, 95% CI 0.37–0.80) whereas CD4 count increase after one year of
treatment was similar in both groups.
Conclusions: Although more than 240 different initial regimens were prescribed, violations of the IAS-USA
recommendations were uncommon. Patients receiving these regimens were less likely to have an undetectable viral
load after one year, which strengthens the validity of these recommendations.
Citation: Wandeler G, Keiser O, Hirschel B, Gu¨nthard HF, Bernasconi E, et al. (2011) A Comparison of Initial Antiretroviral Therapy in the Swiss HIV Cohort Study
and the Recommendations of the International AIDS Society-USA. PLoS ONE 6(12): e27903. doi:10.1371/journal.pone.0027903
Editor: Mark Wainberg, McGill University AIDS Centre, Canada
Received August 18, 2011; Accepted October 27, 2011; Published December 20, 2011
Copyright:  2011 Wandeler et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was financed in the framework of the Swiss HIV Cohort Study, supported by the Swiss National Science Foundation (SNF grant number
33CSC0-108787, SHCS project number 592) (http://www.snf.ch). The funders had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: gwandeler@ispm.unibe.ch
Introduction
After 1996, the use of combined antiretroviral therapy (ART)
transformed HIV infection from a progressive, fatal disease to a
treatable chronic condition and dramatically reduced its related
morbidity and mortality [1,2,3]. By analogy to other chronic
diseases, there was a need for evidence-based treatment recom-
mendations in order to guide clinicians in their decision-making
process thus improving general HIV infection management [4].
Several national and international organisations released recom-
mendations which were updated at short intervals. Although these
treatment guidelines provide valuable, evidence or expert opinion
based information, they are not always followed by clinicians [5].
In 2001, the Swiss Federal Office of Public Health stopped
issuing recommendations [6]. However, the International AIDS
Society-USA has been publishing recommendations at least every
two years since 1998 [7,8,9,10,11,12,13,14,15]. These guidelines
were well accepted in Switzerland.
Even though comprehensive treatment recommendations are
now widely available, choosing an initial antiretroviral combi-
nation often remains a challenging task. In the industrialized
world, the availability of more than twenty different antiretro-
viral drugs has led to highly personalized ART prescriptions,
according to patient characteristics and wishes, co-morbidities
and resistance testing. This contrasts to the public health
approach to ART, as shown by Keiser et al., who compared
initial ART regimens prescribed in South Africa and the SHCS
[16]. Many more first-line combinations were available in
Switzerland compared to South Africa (36 vs. 4), and treatment
changes within the first two years were more frequent in
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Switzerland while virological outcomes were similar in both
populations.
CD4 cell count, viral load and socio-demographic characteris-
tics such as age and ethnicity have been shown to be associated
with the type of ART prescribed and the probability of being
treated with an ART in violation of current guidelines [17,18,19].
The main goal of official treatment guidelines is to improve the
choice of ART. A publication from a small US cohort showed that
patients receiving ART according to the IAS recommendations
had clear virological and immunological benefits [19]. Initial
treatment efficacy also depends on a wide range of socio-
demographic and clinical baseline characteristics. According to a
recent systematic review of initial ART studies, higher treatment
success rates are seen in ‘‘non-white’’ patients and those with low
CD4 cell counts, dual nucleoside backbone and NNRTI or
ritonavir-boosted PI based combinations [20].
The aims of this study were to (1) describe first-line ART
regimens in the SHCS from 1998 to 2007 and compare them with
the corresponding IAS-USA recommendations, (2) describe the
socio-demographic and clinical characteristics of the HIV-infected
sub-population that did not receive regimens consistent with the
IAS-USA recommendations, and (3) compare the efficacy of
regimens prescribed according to these recommendations with
those in violation with them.
Methods
Ethics statement
Local ethical committees of all seven participating study sites
(Kantonale Ethikkommission Bern, Ethikkommission beider Basel
(EKBB), Ethikkommission des Kantons St. Gallen, Kantonale
Ethikkommission Zu¨rich, Comitato etico cantonale del Ticino,
Commission d’e´thique de la recherche clinique de la faculte´ de
biologie et de medicine de l’universite´ de Lausanne, Comite´
d’e´thique du de´partment de me´dicine des hoˆpitaux universitaires
de Gene`ve) have approved the study and written consent has been
obtained from all participants.
Swiss HIV Cohort Study
Set up in 1988, the Swiss HIV Cohort Study (SHCS, www.
shcs.ch) is a prospective cohort study with the ongoing enrolment
of HIV-positive adults in seven outpatient clinics and their
affiliated hospitals and private practice physicians in Switzerland.
It is estimated to cover about 45% of the cumulative number of
HIV infections declared to the Swiss public health authorities and
69% of all patients living with AIDS in Switzerland [21]. Detailed
information on demographics, mode of HIV acquisition, recent
risk behavior (for example intravenous drug use or unprotected
sex with occasional partners), clinical events and treatment is
collected using a standard protocol at registration and then at
intervals of 6 months. Details of the study protocol can be found
elsewhere [21]. CD4 counts, HIV viral load (Roche Amplicor
HIV-1 Monitor Assay) and other laboratory results are obtained
every 3 to 6 months. ART is documented in detail at every
clinical visit and every change in treatment is registered in the
SHCS database. HIV resistance data can be linked with the
SHCS database [22]. All services, including antiretroviral therapy
and laboratory testing, are covered by compulsory health
insurance.
Study population
Of the 4304 treatment-naı¨ve patients (SHCS download July
2010) who started ART between 01.08.1998 and 31.12.2007,
4189 were included in the analysis. Of the 115 patients that were
excluded, 8 received unspecified ART and the remaining 107
patients were women who started treatment because of pregnancy
while having a CD4 count above 200 cells/ml. Unlike patients with
severe immune deficiency, many of these women started treatment
because of the pregnancy and stopped it after having given birth.
These women could therefore not be compared with the other
patients.
Classification of ART regimens
Initial ART regimens were compared with the newest IAS
recommendations available at treatment start date. Updated
recommendations were taken into account from the first day of
the month following the publication. ART regimens were
classified by two experienced physicians as follows: 1) recom-
mended regimen; 2) alternative regimen; 3) active but not yet
recommended regimen; 4) drug combination suggesting primary
resistance (in most cases, regimens consisting of more than 3
drugs); 5) prescription within a study protocol; 6) violation of
recommendations. Any regimen consisting of one or two active
drugs only were considered as violations of the recommenda-
tions. In 1998, only PI-based regimens were recommended. In
2000, NNRTI-based regimens were added to the recommended
treatments list and triple-NRTI regimens were only accepted as
first-line treatments in the 2002 recommendations. We encoun-
tered several difficulties in the classification process. There were
inconsistencies between the presentations of the different
recommendations from one year to the other. For instance,
the recommendations elaborated in 2000 did not mention any
alternative treatments, and the ones released in 2002 did not
specify which combinations of NRTI were to be used or
avoided. Importantly, new drugs and combinations are ap-
proved all year long but are only included in the subsequent
guidelines. To avoid classifying such new, active and safe
regimens as violations of recommendations, we created a
separate category for them (category 3: active but not yet
recommended regimen).
Statistical analyses
All statistical analyses were performed using Stata 10 (Stata
Corp, College Station, USA). Baseline characteristics of patients
receiving violation treatments were compared to all other patients
(categories 1–5). Crude associations between baseline character-
istics and initial regimen type were evaluated using chi-square
tests. Predictors of receiving a violation regimen were then assessed
in a multivariable logistic regression analysis. Explanatory
variables included sex, age category at treatment start (18–30,
31–40, 41–50 or over 50 years old), region of origin (Western
Europe, Sub-Saharan Africa or other), risk group according to
mode of HIV acquisition (Men who have Sex with Men (MSM),
heterosexual, Injection Drug Users (IDU) or other), source of
follow-up (SHCS center or other), CD4 count at treatment
initiation (,200, 200–350 or .350 cells/ml), hepatitis B
antigenemia at baseline (defined as having had at least once a
positive HBsAg), chronic hepatitis C virus (HCV) infection
(defined as positive HCV serology and HCV RNA), plasma
HIV load at baseline (,4, 4–5 or .5 log/ml), education level (low
or high education) and start of ART more than three months
before being included in the SHCS.
The proportion of patients achieving undetectable viral load
after 12 months of ART (closest value between 10 and 18 months),
as well as the CD4 increase during this period, were compared
between patients receiving violation ART and the others, using
multivariable logistic and linear regression analyses respectively.
An undetectable viral load was defined as being less than 400
Initial ART and IAS-USA Recommendations
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copies/ml. In a sensitivity analysis, a threshold of 50 copies/ml
was used. Time to switching of ART was evaluated using a Cox
proportional hazards model.
Multiple imputation was used to impute missing values at
baseline. Imputations were based on logistic and linear regression
models with six dependent variables (region of origin, source of
follow-up, CD4 count at start, active hepatitis B infection, log viral
load at baseline and education level) and six independent variables
(violation of recommendations, sex, treatment initiation period,
age at ART start, transmission group and start of ART 3 or more
months before entering the SHCS). Analyses were run on each of
25 datasets and results were combined with Rubin’s rules. In a
sensitivity analysis we also compared these results with a complete
case analysis.
Table 1. Baseline characteristics of patients who initiated ART in the Swiss HIV Cohort Study between 1998 and 2007.
1998–2000 2000–2002 2002–2004 2004–2006 2006–2007 Total p-value
Baseline characteristics N (%) N (%) N (%) N (%) N (%) N (%)
Sex 0.17
Male 611 (69.3) 712 (65.8) 529 (66.6) 581 (70.3) 421 (69.6) 2854 (68.1)
Female 271 (30.7) 370 (34.2) 265 (33.9) 245 (29.7) 184 (30.4) 1335 (31.9)
Age at start ,0.001
18–30 203 (23.0) 219 (20.2) 189 (23.8) 158 (19.1) 116 (19.2) 885 (21.1)
31–40 421 (47.7) 517 (47.8) 307 (38.7) 304 (36.8) 221 (36.5) 1770 (42.3)
41–50 147 (16.7) 222 (20.5) 187 (23.6) 242 (29.3) 173 (28.6) 971 (23.2)
.50 111 (12.6) 124 (11.5) 111 (14.0) 122 (14.8) 95 (15.7) 563 (13.4)
Region of origin 0.01
NW Europe 610 (69.2) 705 (65.2) 516 (65.1) 513 (62.2) 382 (63.1) 2726 (65.1)
Sub-Saharan Africa 100 (11.3) 178 (16.5) 137 (17.3) 134 (16.2) 101 (16.7) 650 (15.5)
Other 172 (19.5) 199 (18.4) 140 (17.7) 178 (21.6) 122 (20.2) 811 (19.4)
Ethnicity 0.01
Caucasian 696 (78.9) 808 (74.7) 578 (72.8) 625 (75.7) 430 (71.1) 3137 (74.9)
Other 186 (21.1) 274 (25.3) 216 (27.2) 201 (24.3) 175 (28.9) 1052 (25.1)
Risk ,0.001
MSM 298 (33.8) 292 (27.0) 259 (32.6) 318 (38.5) 263 (43.5) 1430 (34.1)
Heterosexual 341 (38.7) 498 (46.0) 394 (49.6) 358 (43.3) 258 (42.6) 1849 (44.1)
IDU 207 (23.5) 246 (22.7) 109 (13.7) 114 (13.8) 54 (8.9) 730 (17.4)
Other 36 (4.1) 46 (4.3) 32 (4.0) 36 (4.4) 30 (5.0) 180 (4.3)
Source of follow-up 0.003
SHCS Center 536 (69.5) 694 (70.9) 534 (72.1) 563 (72.3) 425 (72.8) 2752 (71.4)
Other hospital 86 (11.2) 88 (9.0) 45 (6.1) 47 (6.0) 35 (6.0) 301 (7.8)
Private practitioner 149 (19.3) 197 (20.1) 162 (21.9) 169 (21.7) 124 (21.2) 801 (20.8)
CD4 count at start ,0.001
,200 362 (47.6) 544 (56.1) 381 (52.3) 371 (47.7) 224 (38.4) 1882 (49.3)
200–349 181 (23.8) 247 (25.5) 219 (30.1) 286 (36.8) 244 (41.9) 1177 (30.8)
.= 350 217 (28.6) 178 (18.4) 128 (17.6) 121 (15.6) 115 (19.7) 759 (19.9)
AIDS defining condition before start 196 (22.2) 221 (20.4) 151 (19.0) 165 (20.0) 99 (16.4) 832 (19.9) 0.08
Active hepatitis B infection 60 (7.1) 72 (6.9) 49 (6.3) 47 (5.9) 30 (5.1) 258 (6.4) 0.54
Active hepatitis C infection 147 (16.7) 165 (15.3) 117 (14.7) 117 (14.2) 57 (9.4) 603 (14.4) 0.002
Log viral load at start ,0.001
#4 176 (23.3) 184 (19.1) 151 (20.5) 174 (22.4) 161 (28.0) 846 (22.2)
4–5 304 (40.3) 347 (36.0) 233 (31.7) 262 (33.7) 206 (35.8) 1352 (35.5)
.5 274 (36.3) 432 (44.9) 351 (47.8) 342 (44.0) 209 (36.3) 1608 (42.3)
Education 0.06
no completed school 89 (10.5) 118 (11.3) 84 (10.9) 67 (8.2) 46 (7.7) 404 (9.9)
mandatory school 555 (65.3) 673 (64.5) 475 (61.5) 530 (65.1) 377 (63.2) 2610 (64.0)
higher education 206 (24.2) 252 (24.2) 214 (27.7) 217 (26.7) 174 (29.2) 1063 (26.1)
ART start $3 months before SHCS
inclusion
198 (22.5) 282 (26.1) 221 (27.8) 166 (20.1) 89 (14.7) 956 (22.8) ,0.001
doi:10.1371/journal.pone.0027903.t001
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Results
Baseline characteristics
Baseline socio-demographic and clinical characteristics of the
4,189 HIV-infected patients who started ART between August
1998 and December 2007 are listed in Table 1. At the time of
initiation of therapy, almost half of the patients had an advanced
immune deficiency (CD4 cells below 200/ml) and 20% had already
suffered from an AIDS-defining condition.
Classification of initial regimens
The classification of initial ART regimens according to the IAS-
USA recommendations in force at time of ART start is listed in
Table 2. Overall, 241 different regimens were prescribed during
the study period, the 10 most frequent ones covering two thirds of
the patients. Seventy-three percent of patients started one of the
recommended first-line treatments and 5.2% of the participants
started a regimen in violation with the recommendations. Patients
that started treatment between 1998 and 2002 as well as in2007
were more likely to have regimens considered to be in violation
with the recommendations. Of the 217 patients who initiated a
violation regimen, 53% started a treatment consisting of less than
3 drugs. Fifty-five patients (25%) received a dual NRTI treatment;
the most frequently prescribed being the combination of
zidovudine and lamivudine (32 patients). Of note, the proportion
of dual regimen was highest before 2002. Thirty-four percent of
the patients on violation ART were prescribed a regimen
containing 3 drugs or more but including an NRTI backbone in
violation to IAS-USA recommendations. Only one patient was
prescribed a PI-monotherapy during the study period.
Predictors of recommendation violations
Table 3 shows the baseline characteristics of the 4189 patients
who started ART during the study period and their association
with the use of violation regimens. After adjustment for all
covariables, the odds of receiving a treatment combination in
violation with the most recent IAS-USA recommendations were
higher for women and in highly educated people. Patients who
had a CD4 count above 350 cells/ml at ART start were more
likely and participants with a viral load between 4 and 5 logs were
less likely to receive violation regimens. Those who initiated
treatment between 2002 and 2006 had higher odds of being
prescribed ART according to the recommendations. Finally,
those who started ART more than three months before being
included in the SHCS were more often prescribed violation
regimens. In the complete case analysis including only the 3363
participants (80%) in whom all variables were measured, there
were no major differences in the associations described above
(results not shown).
Comparison of outcomes one year after treatment
initiation
Patients who initiated ART in the SHCS between 1998 and
2007 had a median CD4 count increase of 165 cells/ml (IQR
76-273) within one year, and 85% of them had a viral load
below 400 copies/ml one year after treatment start. Patients
given violation regimens were less likely to achieve an
undetectable viral load (OR: 0.54, 95%CI 0.37–0.80) one year
after treatment start (Table 4). The initiation of therapy after
2002, a high education level and being treated in a peripheral
SHCS site were all associated with having an undetectable viral
load after one year of therapy (online supporting informa-
tion: Table S1). This was also true for patients older than 40
years, compared to those under 30. Patients originating from
Sub-Saharan Africa were less likely to achieve an undetectable
viral load compared to those from Western Europe, as were
IDU’s compared to MSM. Finally, participants starting ART
more than 3 months before enrolment in the SHCS or with a
CD4 count above 350 cells/ml were least likely to have an
undetectable viral load after one year.
Immunological recovery one year after ART start was similar in
both treatment groups (Table 4). The CD4 cell count increased
by 185 cells/ml (95%CI: 179–192) in patients on recommended
regimens and by 152 cells/ml (119–185) in those on violation
regimens. The strongest predictors of CD4 cell count increase
were baseline CD4 count and viral load, calendar time and age at
start, as well as transmission risk group (online supporting
information: Table S2).
Within the first year of treatment, 34% of patients on violation
regimens were switched to a second regimen, as compared to
25% in the other groups. The corresponding adjusted hazard
ratio in the Cox regression model was 1.66 (95% CI 1.25–2.20;
p,0.001).
Sensitivity analyses
When the threshold of HIV viral load was set at 50 copies/ml
instead of 400, the difference in the proportion of patients having a
favourable outcome at one year between the two treatment groups
was not statistically significant. With this second definition,
participants with initial treatment in violation of the recommen-
dations were 25% less likely to reach an undetectable viral load
Table 2. Description of Treatment categories according to the International AIDS Society-USA recommendations.
Period
Number of
regimens Initial treatment categories
recommended alternative
active but not yet
recommended
primary
resistance
prescription
within a study violation total
1998–2000 96 483 (55.1) 78 (8.9) 168 (19.2) 65 (7.4) 11 (1.3) 72 (8.2) 877
2000–2002 103 762 (70.0) 0 (0) 200 (18.5) 50 (4.6) 10 (0.9) 65 (6.0) 1087
2002–2004 64 649 (81.7) 2 (0.3) 104 (13.1) 18 (2.3) 0 (0) 21 (2.6) 794
2004–2006 82 668 (80.9) 88 (10.7) 0 (0) 17 (2.1) 31 (3.8) 22 (2.7) 826
2006–2007 61 496 (82.0) 57 (9.4) 0 (0) 15 (2.5) 0 (0) 37 (6.1) 605
Total 241 3058 (73.0) 225 (5.4) 472 (11.3) 165 (3.9) 52 (1.2) 217 (5.2) 4189
Pearson chi2: p,0.001.
doi:10.1371/journal.pone.0027903.t002
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compared to those on recommended regimens, after adjustment
for all co-factors (aOR 0.75, 95%CI 0.53–1.06). When analyzed
separately, patients on dual-NRTI regimen were also less likely to
reach an undetectable viral load (,400copies/mL) after 1 year
than patients on recommended regimens (aOR 0.44, 95%CI
0.18–1.08).
Table 3. Predictors for receiving an initial ART regimen in violation with the IAS-USA recommendations (N = 4,189).
Basic characteristics Treatment Univariable analysis Multivariable analysis
recommended Violation OR (95%CI) p-value OR (95% CI) p-value
Period
1998–2000 810 (91.8) 72 (8.2) ref. ,0.001 ref. ,0.001
2000–2002 1017 (94.0) 65 (6.0) 0.72 (0.51–1.02) 0.72 (0.50–1.03)
2002–2004 773 (97.4) 21 (2.6) 0.31 (0.19–0.50) 0.30 (0.18–0.49)
2004–2006 804 (97.3) 22 (2.7) 0.31 (0.19–0.50) 0.31 (0.19–0.52)
2006–2007 568 (93.9) 37 (6.1) 0.73 (0.49–1.11) 0.76 (0.49–1.16)
Sex
Male 2728 (95.6) 126 (4.4) ref. 0.001 ref. 0.001
Female 1244 (93.2) 91 (6.8) 1.58 (1.20–2.09) 1.83 (1.28–2.62)
Age at start
18–30 829 (93.7) 56 (6.3) ref. 0.22 ref. 0.85
31–40 1678 (94.8) 92 (5.2) 0.81 (0.58–1.14) 0.91 (0.63–1.30)
41–50 924 (95.2) 47 (4.8) 0.75 (0.51–1.12) 1.05 (0.68–1.62)
.50 541 (96.1) 22 (3.9) 0.60 (0.36–1.00) 0.91 (0.53–1.58)
Region of origin
NW Europe 2592 (95.1) 134 (4.9) ref. 0.55 ref. 0.73
Sub-Saharan Africa 612 (94.1) 38 (5.9) 1.20 (0.83–1.74) 1.15 (0.72–1.83)
Other 766 (94.5) 45 (5.5) 1.14 (0.80–1.61) 1.14 (0.79–1.65)
Risk
MSM 1360 (95.1) 70 (4.9) ref. 0.24 ref. 0.11
Heterosexual 1759 (95.1) 90 (4.9) 0.99 (0.72–1.37) 0.73 (0.47–1.13)
IDU 681 (93.3) 49 (6.7) 1.40 (0.96–2.04) 1.20 (0.77–1.88)
Other 172 (95.6) 8 (4.4) 0.90 (0.43–1.91) 0.66 (0.29–1.46)
Source of follow-up
SHCS Center 2622 (95.3) 130 (4.7) ref 0.20 ref. 0.85
other 1039 (94.3) 63 (5.7) 1.22 (0.90–1.67) 1.03 (0.75–1.42)
CD4 count at start
,200 1814 (96.4) 68 (3.6) ref. 0.004 ref. 0.10
200–349 1122 (95.3) 55 (4.7) 1.31 (0.91–1.88) 1.34 (0.91–1.97)
.= 350 709 (93.4) 50 (6.6) 1.88 (1.29–2.74) 1.53 (1.02–2.30)
Active HBV infection
No 3593 (94.9) 191(5.1) ref 0.59 ref. 0.57
Yes 243 (94.2) 15 (5.8) 1.16 (0.68–2.00) 1.18 (0.67–2.06)
Log viral load at start
,= 4 792 (93.6) 54 (6.4) ref 0.01 ref. 0.09
4–5 1301 (96.2) 51 (3.8) 0.57 (0.39–0.85) 0.62 (0.40–0.95)
.5 1544 (96.0) 64 (4.0) 0.61 (0.42–0.88) 0.70 (0.46–1.08)
Education
no or low education 2873 (95.3) 141 (4.7) ref. 0.04 ref. 0.02
higher education 996 (93.7) 67 (6.3) 1.37 (1.02–1.85) 1.49 (1.07–2.06)
ART $3 mo. before inclusion
No 3093 (95.7) 140 (4.3) ref ,0.001 ref. ,0.001
Yes 879 (91.9) 77 (8.1) 1.94 (1.45–2.58) 1.98 (1.45–2.70)
doi:10.1371/journal.pone.0027903.t003
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Discussion
Since 1998 and the first version of the IAS-USA recommen-
dations, more than four thousand treatment-naı¨ve HIV-infected
patients started ART in the SHCS until the end of 2007, being
prescribed one of more than two hundred different regimens. The
majority of these participants received initial treatment according
to IAS-USA recommendations in force at the time ART was
started, as well as according to IAS-USA recommendations on
antiretroviral drug resistance testing if primary antiretroviral
resistance was shown [23,24,25]. Throughout the whole study
period, 5% of patients received regimens in violation with these
recommendations. In a large cohort of HIV infected US veterans,
it was found that between 1998 and 2004, no patient was treated
with a regimen that violated protocols and that less than 3% of
participants started a regimen with modest activity [18]. The
differences between studies comparing and evaluating ART
guidelines might be explained by differences in HIV cohorts, but
probably to a greater extent by variations in interpretation and use
of international recommendations.
The baseline characteristics of the patients receiving violation
combinations were of special interest, since it was suspected that
these regimens might lead to a higher proportion of viral failures.
In our study, these patients were more often female and highly
educated. Even though it is unknown why these sub-populations
were more likely to receive initial ART in violation of
recommendations, physicians should be aware of these associa-
tions in order to avoid the prescription of these inferior regimens..
Highly educated patients may also have been more active in the
negotiations regarding the choice of the initial treatment regimen
with the physician, favouring sometimes regimens known to be of
low virological efficacy. In their small study of self-reported initial
treatment in a US-cohort of HIV infected women, Cocohoba et al.
reported a significant association between the prescription of
violation regimens in patients with a higher CD4 count and lower
viral load at baseline [19]. Similarly, we found that a CD4 cell
count above 350 cell/ml was a predisposing factor for receiving
such unfavorable regimens. Previous studies showed a high
variability of ART prescription in relation to the year of treatment
initiation, violation regimens being used more frequently in the
early years of the combination ART era [18,19]. In the SHCS,
patients who started ART in the late 90’s were significantly more
likely to receive a violation regimen than those who started after
2000, possibly because of the physician’s lack of experience with
combination ART and international treatment recommendations.
It also seems that the aim of suppressing viral load to levels below
50 copies/ml, was less prominent in the early years of combination
ART, as shown by the significant proportion of dual ART
regimens reported for the first period in this study.
In the SHCS, patients treated according to the IAS-USA
recommendations between 1998 and 2007 were significantly more
likely to achieve an undetectable viral load (,400 cp/mL) after
one year, compared with those on a violation regimen.
Importantly, patients on violation regimens were more likely to
change their treatment to a different regimen during the first six
months of ART. As a consequence, changes from a violation
regimen to a recommended one might have had a positive impact
on clinical outcomes in this sub-group of patients. This might have
decreased the difference in virological outcome between patients
on violation ART and those on recommended regimens. When
the definition of an undetectable viral load was restricted to less
than 50 copies/ml, the association between treatment group and
virological outcome was not statistically significant. Even though
this second definition is widely used in the clinical settings, it may
not be appropriate in this context, as some patients might
experience single episodes of low-level viremia, so-called blips,
which often do not have any clinical consequences. Notably,
IDU’s and patients from Sub-Saharan Africa were less likely to
have an undetectable viral load one year after treatment start
compared to the other risk groups, even though they were not
prescribed violation regimens more often. These associations have
both been described in previous studies and might be explained by
lower treatment adherence, as described in the SHCS by Glass
et al. [26,27]
Another relevant finding of this study relates to the important
role of the SHCS in the daily clinical management of HIV infected
patients in Switzerland. Participants who started ART more than
3 months before being included in the SHCS were more often
prescribed regimens in violation with the recommendations and
were less likely to have an undetectable viral load after one year.
Although this seems to support the management of HIV infected
patients by physicians experienced in the field of HIV medicine,
this finding could also be explained by differences in access to care
or other socio-economic factors.Finally, immunological response
to ART in patients on violation regimens showed a less favorable
trend compared to CD4 recovery in patients on recommended
initial ART, although the difference was not statistically significant
Table 4. Virological and immunological outcomes one year after ART start.
Outcome Univariable analysis Multivariable analysis
OR (95%CI) p-value OR (95% CI) p-value
Virologically suppressed
(,400 copies/mL) 1 year after ART start
(N=3,643)
Violation regimen
No ref. ,0.001 ref. 0.002
Yes 0.47 (0.33, 0.68) 0.54 (0.37, 0.80)
Average CD4 count change (cells/ml)
1 year after ART start
(N=3,171)
Violation regimen
No ref. 0.03 ref. 0.11
Yes 232.9 (263.3, 225) 223.9 (253.2, 5.4)
doi:10.1371/journal.pone.0027903.t004
Initial ART and IAS-USA Recommendations
PLoS ONE | www.plosone.org 6 December 2011 | Volume 6 | Issue 12 | e27903
in the multivariable model. As expected, younger patients and
those with a low CD4 count at baseline had a better immunologic
recovery than the others.
There are several limitations to this study. First, it has to be
noted that our classification of the different initial ART regimens
in the SHCS was based on expert judgement and not on pre-
specified objective criteria. Second, detailed description of
antiretroviral combinations is not available in every set of
recommendations thus allowing for a wider range of treatments
accepted in the different treatment categories depending on the
year of release. Third, our statistical analyses rely on observational
data, which leads to different types of bias. For example, data on
patient history is only collected twice a year, and is therefore
subject to recall bias. CD4 counts and viral load values were not
always obtained exactly 12 months after ART initiation, the ones
measured closest to this time period had to be used. Finally, the
logistic regression models cannot be adjusted for every single
existing confounder, which means that residual confounding has to
be taken into account when interpreting the results. Finally, given
the large amount of ART-related issues discussed in the IAS-USA
treatment recommendations, we could not consider all determi-
nants of ART prescription for our analyses. As a consequence,
even though possible adverse events and pill count, for instance,
should be considered when choosing the appropriate initial ART
regimen, we decided to limit our analyses to the description of
individual predictors for receiving violation regimens and the
evaluation of the virological and immunological response to the
different ART regimens.
In summary, our results show that in the SHCS, 5% of patients
received initial regimens in violation with the IAS-USA recom-
mendations. These patients were less likely to achieve viral load
suppression after one year. Our results suggest that, in the context
of constant increase in the number of therapeutic options and
knowledge on specific drug-related side-effects and interactions,
the release of updated treatment recommendations as well as the
promotion of their use are important to guarantee the best possible
care of HIV infected patients.
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